Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.
Murong WangQunfang ZhouHui LiMingyu LiuRuixia LiWei WangXiao-Hui WangJinhua HuangFeng DuanPublished in: ImmunoTargets and therapy (2024)
Lenvatinib combined with PD-1 inhibitor significantly improves the survival of HCC beyond oligometastasis. For patients with HAIC, there was obviously significance between Len and Len+PD-1 groups.